CL is the ticker symbol for COLGATE PALMOLIVE CO, a publicly traded Consumer Staples sector company listed on NYSE. 13F Pro tracks CL with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is CL a good stock to buy?

13F Pro's AI ranking engine scores CL at 60.9/100, ranked #828 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for CL is available at https://13fpro.ai/company/CL. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source CL data?

All COLGATE PALMOLIVE CO fundamentals and ownership data come directly from SEC EDGAR. COLGATE PALMOLIVE CO files with the SEC under CIK 21665. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

COLGATE PALMOLIVE CO CL

NYSELarge CapConsumer Staples

13F Pro quality score

Rank #828 of 2,925TOP 50%

Why it scores 61 Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$5.36B

Quarter to Jun 30

Net income

$693.00M

Quarter to Jun 30

Free cash flow

$867.00M

Quarter to Jun 30

Operating margin

18.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$61.51B total

BlackRock, Inc.

$6.41B-3.8%

VANGUARD CAPITAL MANAGEMENT LLC

$4.79B+0.1%

STATE STREET CORP

$4.31B-1.5%

PRICE T ROWE ASSOCIATES INC /MD/

$2.56B-17.3%

VANGUARD PORTFOLIO MANAGEMENT LLC

$2.20B+0.8%

GEODE CAPITAL MANAGEMENT, LLC

$2.14B+1.1%

MORGAN STANLEY

$2.02B+5.7%

Bank of New York Mellon Corp

$1.24B+8.1%

DEUTSCHE BANK AG\

$1.08B-1.5%

NORGES BANK

$888.02M--

ACADIAN ASSET MANAGEMENT LLC

$833.94M+14.6%

FMR LLC

$823.57M-0.3%

GOLDMAN SACHS GROUP INC

$785.79M-9.5%

NORTHERN TRUST CORP

$776.67M-2.4%

Invesco Ltd.

$763.29M-0.2%

First Eagle Investment Management, LLC

$752.30M+1.1%

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

$617.06M0.0%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$593.30M-5.2%

Amundi

$570.09M+19.9%

BANK OF AMERICA CORP /DE/

$567.48M-6.7%

ROYAL BANK OF CANADA

$512.62M+13.2%

Legal & General Group Plc

$496.57M-5.3%

DIMENSIONAL FUND ADVISORS LP

$488.59M+2.7%

AMERIPRISE FINANCIAL INC

$479.14M+0.5%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$471.98M+0.5%

See all 2,031 institutional holders →

What's Driving CL's Business? Latest 10-Q Breakdown

48/48 datapoints verified

AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 4.9% to $5,361M on 2.4% organic growth, but $129M of Strategic Growth and Productivity Program charges cut operating profit 6% to $1,016M.

Biggest Revenue Drivers

Latin America (Oral, Personal and Home Care)$1,372M+13.7% YoY

Volume growth of 2.6%, net selling price increases of 2.8% and positive foreign exchange of 8.4%; organic growth led by Mexico, Brazil and Argentina.

Hill's Pet Nutrition$1,195M+3.4% YoY

Net selling price increases of 3.9% and positive foreign exchange of 0.6%, partially offset by volume declines of 1.2%; growth in therapeutic and wellness categories.

Biggest Revenue Drivers

Total revenue: $5,361M+4.9% YoY

Latin America (Oral, Personal and Home Care)$1,372M+13.7% YoY

Volume growth of 2.6%, net selling price increases of 2.8% and positive foreign exchange of 8.4%; organic growth led by Mexico, Brazil and Argentina.

Hill's Pet Nutrition$1,195M+3.4% YoY

Net selling price increases of 3.9% and positive foreign exchange of 0.6%, partially offset by volume declines of 1.2%; growth in therapeutic and wellness categories.

Europe, Middle East & Africa (Oral, Personal and Home Care)$1,121M+3.5% YoY

Volume growth of 3.2% and positive foreign exchange of 1.6%, partially offset by net selling price decreases of 1.2%; led by Türkiye, Germany, UK and Italy.

North America (Oral, Personal and Home Care)$891M-3.0% YoY

Volume declines of 3.9% partially offset by net selling price increases of 0.9%; decline driven by the United States, mainly toothpaste, bar soap and body wash.

Asia Pacific (Oral, Personal and Home Care)$782M+4.9% YoY

Volume growth of 4.1% and net selling price increases of 1.1%; organic growth driven by India, the Greater China region and the Philippines.

Largest Expense Items

Selling, general and administrative expenses$2,130M+9% YoY

Increased advertising investment of $99 and higher overhead expenses of $60; advertising rose to 14.5% of net sales from 13.3%.

Cost of sales$2,065Mvs. $2,041M prior-year quarter

Gross margin gained from funding-the-growth savings (280 bps), partly offset by higher raw and packaging material costs (220 bps) including tariff impacts.

Other (income) expense, net$150Mvs. $26M prior-year quarter

Included $120 of charges resulting from the Strategic Growth and Productivity Program; excluding these, $30 versus $17 a year ago.

Margins: Gross profit margin rose 140 bps to 61.5%, driven by funding-the-growth savings (280 bps), pricing (60 bps) and mix (20 bps), offset by higher raw and packaging costs (220 bps). GAAP operating margin fell 210 bps to 19.0% on restructuring charges.

Watch Items from the Filing

Strategic Growth and Productivity Program cost $129 pre-tax this quarter; cumulative pre-tax charges are estimated at $350 to $550 through December 31, 2028.
North America net sales fell 3.0% to $891 on volume declines of 3.9%; management expects category softness to continue through the second half of 2026.
Talcum powder cases pending rose to 525 at June 30, 2026 from 484 at March 31 and 453 at December 31, 2025; 84 new cases filed this quarter.
Aggregate reasonably possible losses in excess of accrued liabilities estimated at $0 to approximately $225, plus Brazilian tax assessments of roughly $105 and $28.
Approximately two-thirds of net sales are outside the United States and roughly 45% from emerging markets, with acute FX volatility in Argentina, Nigeria and Türkiye.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CL

Earnings Per Share

13fpro.ai/company/CL

Loading ratio trend…

COLGATE PALMOLIVE CO reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$20.4B	$2.1B	16.2%
FY 2024	10-K	$20.1B	$2.9B	21.2%
FY 2023	10-K	$19.5B	$2.3B	20.5%
FY 2022	10-K	$18.0B	$1.8B	16.1%
FY 2021	10-K	$17.4B	$2.2B	19.1%
FY 2020	10-K	$16.5B	$2.7B	23.6%

About COLGATE PALMOLIVE CO (CL): stock profile, AI score and financials

COLGATE PALMOLIVE CO (CL) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores CL at 60.9/100 on a composite quality score built from its SEC filings, placing it at rank #828 of 2,925 stocks — the top half of the AI-ranked universe. CL scores in the top quartile across revenue scale (92.7), balance sheet strength (88.8). Areas of concern include revenue growth (33.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), COLGATE PALMOLIVE CO reports quarterly revenue of $5.4B, net income of $693.0M, an operating margin of 18.9%. Top institutional holders of CL by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. CL trades on the NYSE exchange and files with the SEC under CIK 21665. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COLGATE PALMOLIVE CO directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 21665 →

COLGATE PALMOLIVE CO CL

Top Institutional Holders

What's Driving CL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

CL key financials by period

CL insiders

Congress trading in CL

About COLGATE PALMOLIVE CO (CL): stock profile, AI score and financials

COLGATE PALMOLIVE CO CL

Top Institutional Holders

What's Driving CL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

CL key financials by period

Companies similar to CL

CL insiders

Congress trading in CL

About COLGATE PALMOLIVE CO (CL): stock profile, AI score and financials